Bayer Bags Full Vitrakvi Rights As Lilly Signs Off Loxo Buy
Executive Summary
When buying Loxo, Lilly highlighted the importance of LOXO-292, a first-in-class oral RET inhibitor, rather than the already-approved Vitrakvi, perhaps knowing that partner Bayer was going to be exercising an option to take full control of the TRK inhibitor.
You may also be interested in...
Lilly Oncology President Anne White On Loxo Success, What’s To Come
White said the late 2019 creation of Loxo Oncology at Lilly to spearhead cancer R&D has exceeded her expectations. The executive also discussed COVID-19’s impact on drug sales and cancer screening.
Lilly's Loxo Bet Pays Off In Thyroid Cancer, A Second Indication For Selpercatinib
The company reported positive Phase III response rate data weeks after strong results in lung cancer for the RET inhibitor also known as LOXO-292. An NDA submission is on track for later this year.
Lilly Moves Closer To NDA Filing For RET Inhibitor In NSCLC
Lilly hopes to bring Loxo’s tissue-agnostic RET inhibitor selpercatinib to market in 2020.